Evaluation of alginate purification methods: Effect on polyphenol, endotoxin, and protein contamination

Journal of Biomedical Materials Research - Part A - Tập 76A Số 2 - Trang 243-251 - 2006
Julie Dusseault1,2, Susan K. Tam2,3, Martin Ménard1, Stéfania Polizu3, Guillaume Jourdan1, L’Hocine Yahia4,3, Jean‐Pierre Hallé1,4
1Centre de recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada, H1T 2M4
2J. Dusseault and S. K. Tam contributed equally to this work
3Laboratoire d'analyse et d'innovation de bioperformance, École Polytechnique, Montréal, Québec, Canada, H3T 1J4
4L. Yahia and J.-P. Hallé contributed equally to this work

Tóm tắt

AbstractAlginate, a polysaccharide extracted from brown seaweed, is widely used for the microencapsulation of islets of Langerhans, allowing their transplantation without immunosuppression. This natural polymer is known to be largely contaminated. The implantation of islets encapsulated using unpurified alginate leads to the development of fibrotic cell overgrowth around the microcapsules and normalization of the blood glucose is restricted to a very short period if it is achieved at all. Several research groups have developed their own purification method and obtained relatively good results. No comparative evaluation of the efficiencies of these methods has been published. We conducted an evaluative study of five different alginate preparations: a pharmaceutical‐grade alginate in its raw state, the same alginate after purification according to three different published methods, and a commercially available purified alginate. The results showed that all purification methods reduced the amounts of known contaminants, that is, polyphenols, endotoxins, and proteins, although with varying efficiencies. Increased viscosity of alginate solutions was observed after purification of the alginates. Despite a general efficiency in decreasing contamination levels, all of the purified alginates contained relatively high residual amounts of protein contaminants. Because proteins may be immunogenic, these residual proteins may have a role in persisting microcapsule immunogenicity. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res, 2006

Từ khóa


Tài liệu tham khảo

10.1126/science.6776628

10.1016/j.tibtech.2003.11.004

Lum ZP, 1991, Prolonged reversal of diabetic state in NOD mice by xenografts of microencapsulated rat islets, Diabetes, 40, 1511, 10.2337/diab.40.11.1511

Soon‐Shiong P, 1991, An immunologic basis for the fibrotic reaction to implanted microcapsules, Transplant Proc, 23, 758

10.1097/00007890-199206000-00002

Darquy S, 1990, Comparative study of microencapsulated rat islets implanted in different diabetic models in mice, Horm Metab Res, 25, 209

10.1097/00007890-199002000-00034

Weber C, 1994, NOD mouse peritoneal cellular response to poly‐L‐lysine‐alginate microencapsulated rat islets, Transplant Proc, 26, 1116

10.1097/00007890-199104000-00002

10.1007/BF00400270

10.1097/00007890-199610150-00004

10.1097/00007890-199610150-00003

Horcher A, 1994, Transplantation of microencapsulated islets in rats: evidence for induction of fibrotic overgrowth by islet alloantigens released from microcapsules, Transplant Proc, 26, 784

10.1177/096368979700600405

10.1097/00007890-200007270-00025

10.1163/156856293X00294

10.1016/j.biomaterials.2004.05.013

10.1007/s10856-005-0523-2

10.1038/nm0103-104

10.1097/01.TP.0000053749.36365.7E

10.2337/diab.38.1.S224

10.1007/BF00400922

10.1007/s001250050673

10.1111/j.1749-6632.2001.tb03833.x

10.1111/j.1749-6632.1997.tb52197.x

10.1007/BF00173321

10.1016/S0142-9612(03)00299-0

10.1007/s002530050012

10.1177/096368979400300503

10.1080/02652040010018137

10.1111/j.1749-6632.2001.tb03832.x

10.1002/bit.260330112

Pedersen SS, 1989, Purification, characterization, and immunological cross‐reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis, J Clin Microbiol, 27, 691, 10.1128/jcm.27.4.691-699.1989

10.1002/elps.1150130156

Miller A, 1996, Antioxidant flavonoids: structure, function and clinical usage, Altern Med Rev, 1, 103

10.1016/S1367-5931(02)00375-7

10.1515/BOT.1999.051

W.H.O., 1994, Environmental health criteria 161‐phenols

10.1016/S0045-6535(02)00403-4

European Pharmacopoeia.Strasbourg: European department for the quality of medicines within the council of Europe;1997.

Surialink, 2001, Overview of sea vegetable chemical composition, Bulletin, 1

Godek ML, 2004, Morphology and growth of murine cell lines on model biomaterials, Biomed Sci Instrum, 40, 7

10.1002/(SICI)1097-4636(19990915)46:4<582::AID-JBM17>3.0.CO;2-5

10.1080/0265204031000140796

Thông tin
Thông tin xuất bản

Journal of Biomedical Materials Research - Part A

Tập 76A Số 2

243-251

Thông tin tác giả